AKTX
Price
$8.23
Change
-$0.53 (-6.05%)
Updated
Oct 22 closing price
Capitalization
16.02M
21 days until earnings call
Intraday BUY SELL Signals
CVKD
Price
$0.97
Change
-$0.05 (-4.90%)
Updated
Oct 22 closing price
Capitalization
3.46M
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AKTX vs CVKD

AKTX vs CVKD Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AKTX vs. CVKD commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKTX is a Buy and CVKD is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AKTX with price predictions
Oct 22, 2026

AKTX's RSI Oscillator ascending out of oversold territory

The RSI Indicator for AKTX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 36 of the 39 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for AKTX just turned positive on October 20, 2026. Looking at past instances where AKTX's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.

The 50-day moving average for AKTX moved above the 200-day moving average on October 21, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKTX advanced for three days, in 153 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

AKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 41 cases where AKTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKTX as a result. In 96 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

AKTX moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AKTX crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for AKTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. AKTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.862) is normal, around the industry mean (2.973). AKTX's P/E Ratio (95.710) is considerably higher than the industry average of (-1.705). Projected Growth (PEG Ratio) (1.890) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for CVKD with price predictions
Oct 22, 2026

CVKD's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for CVKD turned positive on September 17, 2026. Looking at past instances where CVKD's MACD turned positive, the stock continued to rise in 30 of 35 cases over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CVKD's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on CVKD as a result. In 46 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

Following a +16.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVKD advanced for three days, in 144 of 178 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 40 cases where CVKD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

CVKD broke above its upper Bollinger Band on September 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CVKD entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.846) is normal, around the industry mean (2.973). P/E Ratio (-0.199) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. CVKD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
AKTX: Fundamental Ratings
AKTX
OUTLOOK RATING
1..100
4
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
4
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKTXCVKD
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
72%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (AKTX: $8.76 vs. CVKD: $1.02)
Brand notoriety: AKTX and CVKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKTX: 32% vs. CVKD: 5%
Market capitalization -- AKTX: $16.02M vs. CVKD: $3.46M
AKTX [@Biotechnology] is valued at $16.02M. CVKD’s [@Biotechnology] market capitalization is $3.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKTX’s FA Score shows that 1 FA rating(s) are green while CVKD’s FA Score has 1 green FA rating(s).

  • AKTX’s FA Score: 1 green, 4 red.
  • CVKD’s FA Score: 1 green, 4 red.
According to our system of comparison, both AKTX and CVKD are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKTX’s TA Score shows that 6 TA indicator(s) are bullish while CVKD’s TA Score has 4 bullish TA indicator(s).

  • AKTX’s TA Score: 6 bullish, 5 bearish.
  • CVKD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AKTX is a better buy in the short-term than CVKD.

Price Growth

AKTX (@Biotechnology) experienced а +20.66% price change this week, while CVKD (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

AKTX is expected to report earnings on Nov 12, 2026.

CVKD is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
AKTX
Daily Signal:
Gain/Loss:
CVKD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

AKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKTX has been loosely correlated with CNTN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if AKTX jumps, then CNTN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKTX
1D Price
Change %
AKTX100%
-6.05%
CNTN - AKTX
34%
Loosely correlated
-3.63%
KPRX - AKTX
30%
Poorly correlated
-2.09%
QURE - AKTX
29%
Poorly correlated
+1.85%
GOVX - AKTX
27%
Poorly correlated
-8.40%
CVKD - AKTX
25%
Poorly correlated
-4.90%
More

CVKD and

Correlation & Price change

A.I.dvisor tells us that CVKD and RADX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVKD and RADX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVKD
1D Price
Change %
CVKD100%
-4.90%
RADX - CVKD
31%
Poorly correlated
-6.11%
GDTC - CVKD
29%
Poorly correlated
+1.72%
ABUS - CVKD
26%
Poorly correlated
+0.72%
ARTL - CVKD
26%
Poorly correlated
-0.39%
OKUR - CVKD
26%
Poorly correlated
+12.17%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HLNE85.312.85
+3.46%
Hamilton Lane
CAC57.861.45
+2.58%
Camden National Corp
TDAC10.850.04
+0.37%
Translational Development Acquisition Corp.
WDS22.87-0.75
-3.18%
Woodside Energy Group Limited
QNME0.44-0.04
-7.91%
Quanome Technologies Inc